🎢 Your Options Alert for Dec 1 (Monday)

🔮 Analysts Forecast 5x Upside: A Game-Changing Biotech Story Unfolding (ad)*

Dear Reader,

I hope you are having a great Monday and also hope you had a great weekend! I am sending you the list of options signals for the next trading day (to help you cut your research in finding trading and/or investing opportunities).

With a $7 Valuation, NNVC Could Disrupt the Biotech Space in 2026 (ad)*

NNVC is heating up fast. NV-387 is moving into Phase 2 trials — and Zacks Small Cap Research now assigns a $7 target, citing its strong safety profile and broad antiviral potential. With government procurement, biodefense demand, and non-dilutive BARDA funding all on the table, NanoViricides could be on the verge of a multi-billion-dollar breakthrough.

Get the full story before Wall Street catches on.

Stock Name	Signal Date	Signal Name
MA	Dec 1	Golden Crossover
BKNG	Dec 1	Golden Crossover
UL	Dec 1	Golden Crossover
CB	Dec 1	Golden Crossover
BSK	Dec 1	Below 200-MA
STRC	Dec 1	Below 200-MA
XYZ	Dec 1	Below 200-MA
IR	Dec 1	Below 200-MA
MSFT	Dec 1	Double Top
JPM	Dec 1	Double Top
HOOD	Dec 1	Double Top
IBKR	Dec 1	Double Top
CHD	Dec 1	Double Bottom
RYAN	Dec 1	Double Bottom
PEN	Dec 1	Double Bottom
NJR	Dec 1	Double Bottom
Click Here to View Your Full Report

⚡ Could NNVC Be the Next Biotech Giant? (ad)*

NV-387, NanoViricides’ breakthrough antiviral, is advancing to Phase 2 with broad potential across MPox, RSV, flu, and biodefense. With strong safety data and Zacks assigning a $7 valuation, NNVC is entering a pivotal growth window.

🎯 Discover why this platform could redefine antiviral medicine.

How to use signals in your trading/investing strategies:

Options Trading - if you are an Options trader, you can use the Ride-the-Wave strategy (to target multi-day price momentum following a company's trade signal) or the Price Reversal strategy (to target the reversal following signal generation). Please click on Ride-the-Wave Strategy to learn more about it.

Stock Trading - If you're a swing stock trader/investor or portfolio manager, you may want to consider entering or exiting your positiosn based on a the signal generation. Please click on Volatility Crush Strategy to learn more about it.

🤖💰 Virtually Unknown AI Company Solving Trillion-Dollar Problem (ad)

The David to Nvidia's Goliath: Tiny Startup Solving AI's Biggest Challenge

While Nvidia grabs the headlines, a little-known company is quietly reshaping the AI landscape. Their cutting-edge technology is tackling the biggest bottleneck in AI adoption, attracting customers like Intel, AMD, Microsoft, and more. As the AI boom accelerates, this tiny startup could be the ultimate winner.

Get in early on the AI revolution's best-kept secret.

At Options Hero, we're really excited to help you trade more confidently. To that end, we're constantly developing new content to go alongside our platform insights, which will further our mission to help you become a better trader.

To your trading success,

Support Team

Options Hero

PS:Options Hero is morning newsletter, powered by StockEarnings proprietary technology.

URGENT: Trump's AI Policy Shift

Massive manufacturing reshoring is coming

FREE report just released → Get your copy before it's too late

(ad)* This message is a PAID ADVERTISEMENT for NanoViricides, Inc (NYSE: NNVC) from Interactive Offers. Options Hero, Inc and StockEarnings, Inc has received a fixed fee of $4000 from Interactive Offers for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between Dec 01, 2025 and Dec 05, 2025. Other than the compensation received for this advertisement sent to subscribers, Options Hero and StockEarnings and its principals are not affiliated with either NanoViricides, Inc (NYSE: NNVC) or Interactive Offers. Options Hero and StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Options Hero and StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Options Hero and StockEarnings to buy or sell any security. Options Hero and StockEarnings has not evaluated the accuracy of any claims made in this advertisement. Options Hero and StockEarnings recommends that investors do their own independent research and consult with a qualified investment

(ad)* This message is a PAID ADVERTISEMENT for Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) from Market Jar Media Inc. Options Hero, Inc and StockEarnings, Inc has received a fixed fee of $4000 from Market Jar Media Inc for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between Dec 01, 2025 and Dec 05, 2025. Other than the compensation received for this advertisement sent to subscribers, Options Hero and StockEarnings and its principals are not affiliated with either Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) or Market Jar Media Inc. Options Hero and StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Options Hero and StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Options Hero and StockEarnings to buy or sell any security. Options Hero and StockEarnings has not evaluated the accuracy of any claims made in this advertisement. Options Hero and StockEarnings recommends that investors do their own independent research and consult with a qualified investment

Options Hero is a subsidiary of StockEarnings, Inc (SE). SE is a research service not owned or managed by registered brokers and therefore this site does not make any investment recommendations. The information provided in this newsletter is not guaranteed as to the accuracy or completeness. Each user of SE chooses to do trades at their sole discretion and risk. SE is not responsible for gains/losses that may result in the trading of these securities.

This newsletter includes paid advertisements. The source of all third-party content in which SE receives some sort of compensation, is clearly and prominently identified herein as "ad" or "Sponsored". Although we have sent you these advertisements, SE does not specifically endorse any third-party product nor is it responsible for the content of the advertisement or the experience with the third-party advertiser. Furthermore, we make no guarantee or warranty about what is advertised.

All investments involve risk, losses may exceed the principal invested, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Please click here for SE Disclaimers.

🎢 Your Options Alert for Dec 1 (Monday)

0 Response to "🎢 Your Options Alert for Dec 1 (Monday)"

Post a Comment